On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review

Off-label intravitreal use of the vascular endothelial growth factor (VEGF) antibody bevacizumab for retinopathy of prematurity (ROP) increases despite lack of studies on safety, pharmacokinetics and dosage in developing individuals. Systemic absorption has been considered negligible. A literature s...

Descripción completa

Detalles Bibliográficos
Autores principales: Hård, Anna-Lena, Hellström, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263420/
https://www.ncbi.nlm.nih.gov/pubmed/21854449
http://dx.doi.org/10.1111/j.1651-2227.2011.02445.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263420/
https://www.ncbi.nlm.nih.gov/pubmed/21854449
http://dx.doi.org/10.1111/j.1651-2227.2011.02445.x

Ejemplares similares